Key Takeaways
- Amphastar Pharmaceuticals has entered a supply agreement with Nanjing Letop Biotechnology.
- The company reported Q4 2025 revenue of $183.1 million, below analyst expectations.
- Amphastar continues to expand its product pipeline, focusing on generic and injectable medications.
Recent Developments at Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, a biopharmaceutical company specializing in generic and injectable medications, announced a supply agreement with Nanjing Letop Biotechnology on March 3, 2026. This agreement aims to enhance Amphastar’s distribution capabilities and product offerings in the biopharmaceutical market.
In its latest earnings report for Q4 2025, Amphastar revealed revenues of $183.1 million, which fell short of the FactSet estimate of $190.1 million. The company’s adjusted earnings per share (EPS) stood at $0.73, compared to the expected $0.92. This performance reflects ongoing challenges in meeting market expectations, despite a diversified product portfolio.
Amphastar operates primarily in two segments: finished pharmaceutical products and active pharmaceutical ingredients (API). Their portfolio includes essential drugs like Primatene MIST, epinephrine, glucagon, and naloxone, primarily used in hospital settings. The company’s API segment focuses on manufacturing insulin and other key ingredients for internal and external use.
Additionally, Amphastar has a robust pipeline of over 20 product candidates that includes generic abbreviated new drug applications (ANDAs) and biosimilars. The company aims to maintain its competitive edge through continuous development and innovation in the pharmaceutical landscape.
Market analysts have noted the biopharma sector’s improving outlook as Amphastar navigates through these challenging times. Following the recent performance, BofA Securities adjusted its price target for Amphastar from $31 to $30, keeping a neutral rating on the stock. The adjustment reflects cautious optimism regarding the company’s ongoing projects and market conditions.
As Amphastar develops its product line and strengthens strategic partnerships, investors are encouraged to keep an eye on its performance metrics and project updates. The biopharmaceutical landscape remains dynamic, and companies like Amphastar are crucial in meeting both healthcare needs and market demand.
The content above is a summary. For more details, see the source article.